...
首页> 外文期刊>Cancer biology & therapy >Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay
【24h】

Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay

机译:微流控芯片分离肝癌活循环肿瘤细胞的培养及药敏试验

获取原文
获取原文并翻译 | 示例
           

摘要

Circulating tumor cells (CTCs) have been proposed to be an active source of metastasis or recurrence of hepatocellular carcinoma (HCC). The enumeration and characterization of CTCs has important clinical significance in recurrence prediction and treatment monitoring in HCC patients. We previously developed a unique method to separate HCC CTCs based on the interaction of the asialoglycoprotein receptor (ASGPR) expressed on their membranes with its ligand. The current study applied the ligand-receptor binding assay to a CTC-chip in a microfluidic device. Efficient capture of HCC CTCs originates from the small dimensions of microfluidic channels and enhanced local topographic interactions between the microfluidic channel and extracellular extensions. With the optimized conditions, a capture yield reached > 85% for artificial CTC blood samples. Clinical utility of the system was further validated. CTCs were detected in all the examined 36 patients with HCC, with an average of 14 +/- 10/2 mL. On the contrary, no CTCs were detected in healthy, benign liver disease or non-HCC cancer subjects. The current study also successfully demonstrated that the captured CTCs on our CTC-chip were readily released with ethylene diamine tetraacetic acid (EDTA); released CTCs remained alive and could be expanded to form a spheroid-like structure in a 3-dimensional cell culture assay; furthermore, sensitivity of released CTCs to chemotherapeutic agents (sorafenib or oxaliplatin) could be effectively tested utilizing this culture assay. In conclusion, the methodologies presented here offer great promise for accurate enumeration and easy release of captured CTCs, and released CTCs could be cultured for further functional studies.
机译:已经提出循环肿瘤细胞(CTC)是肝细胞癌(HCC)转移或复发的活跃来源。 CTC的计数和表征在HCC患者的复发预测和治疗监测中具有重要的临床意义。我们之前根据其膜上表达的去唾液酸糖蛋白受体(ASGPR)与配体的相互作用,开发了一种独特的方法来分离HCC CTC。当前的研究将配体-受体结合测定应用于微流体装置中的CTC芯片。 HCC CTC的有效捕获源于微流体通道的小尺寸以及微流体通道与细胞外延伸之间增强的局部地形相互作用。在优化的条件下,人工CTC血样的捕获率达到> 85%。该系统的临床实用性得到了进一步验证。在所有接受检查的36例HCC患者中均检测到CTC,平均为14 +/- 10/2 mL。相反,在健康,良性肝病或非HCC癌症受试者中未检测到CTC。当前的研究还成功地证明,在我们的CTC芯片上捕获的四氯化碳很容易与乙二胺四乙酸(EDTA)释放。释放的四氯化碳仍然活着,并且可以在3维细胞培养测定法中扩增成类球体结构。此外,可以利用该培养测定法有效地测试释放的CTC对化学治疗剂(索拉非尼或奥沙利铂)的敏感性。总之,此处介绍的方法为准确枚举和轻松释放捕获的四氯化碳提供了广阔的前景,可以对释放的四氯化碳进行培养,以进行进一步的功能研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号